Investorsatril

Investorsatril

Roopa Industries || Details of Business

Roopa Industries Limited

(CIN: L10100AP1985PLC005582)

  • About Us
  • Management
  • Investor Relations
    • Annual Reports
      • Annual Report – 2023-24
      • Annual Report – 2022-23
      • Annual Report – 2021-22
      • Annual Report – 2020-21
      • Annual Report – 2019-20
      • Annual Report – 2018-19
      • Annual Report – 2017-18
      • Annual Report – 2016-17
      • Annual Report – 2015-16
      • Annual Report – 2014-15
    • Annual Return
      • Form MGT-7- Annual Return for FY 2023-24
      • Form MGT-7 – Annual Return for FY 2022-23
      • Form MGT-7 – Annual Return for FY 2021-22
      • Form MGT-7 – Annual Return for FY 2020-21
      • Form MGT-7 – Annual Return for FY 2019-20
      • Form MGT-7 – Annual Return for FY 2018-19
    • Financial Results
      • Q4 Results – FY 2024-25
      • Q3 Results – FY 2024-25
      • Q2 Results – FY 2024-25
      • Q1 Results – FY 2024-25
      • Q4 Results – FY 2023-24
      • Q3 Results – FY 2023-24
      • Q2 Results – FY 2023-24
      • Q1 Results – FY 2023-24
      • Q4 Results – FY 2022-23
      • Q3 Results – FY 2022-23
      • Q2 Results – FY 2022-23
      • Q1 Results – FY 2022-23
      • Q4 Results – FY 2021-22
      • Q3 Results – FY 2021-22
      • Q2 Results – FY 2021-22
      • Q1 Results – FY 2021-22
      • Q4 Results – FY 2020-21
      • Q3 Results – FY 2020-21
      • Q2 Results – FY 2020-21
      • Q1 Results – FY 2020-21
    • Policies & Codes
      • Nomination and Remuneration Policy
      • Policy On Materiality
      • Whistle Blower Policy
      • Terms and Conditions for appointment of Independent Directors
      • Familiarization Programme
      • Policy for Preservation of Documents
      • Code of Conduct for Board and Senior Management
      • Policy for Materiality of Events
    • Investor Information
      • Board Notices
        • Notice of BM on 30-05-2025
        • Notice of BM on 14-02-2025
        • Notice of BM on 14-08-2024
        • Notice of BM on 30-05-2024
        • Notice of BM on 12-02-2024
        • Notice of BM on 14-11-2023
        • Notice of BM on 12-08-2023
        • Notice of BM on 30-05-2023
        • Notice of BM on 14-02-2023
        • Notice of BM on 13-08-2022
        • Notice of BM on 30-05-2022
        • Notice of BM on 12-02-2022
        • Notice of BM on 13-11-2021
        • Notice of BM on 14-08-2021
      • Other Information
        • MOA & AOA
        • Forms for Updation of KYC
        • Letter to Shareholders 05/03/2024
    • AGM/EGM Information
      • AGM
        • 39th AGM – Voting Results
        • 39th AGM Notice for FY 2023-24
        • 38th AGM – Voting Results
        • 38th AGM Notice for FY 2022-23
        • 37th AGM – Voting Results
        • 37th AGM Notice for FY 2021-22
        • 36th AGM – Voting Results
        • 36th AGM Notice for FY 2020-21
        • 35th AGM – Voting Results
        • 35th AGM Notice for FY 2019-20
        • 34th AGM – Voting Results
        • 34th AGM Notice for FY 2018-19
      • EGM
      • Postal Ballot
        • Voting Results of PB dated on 22-08-2022
        • Notice of PB on 19-07-2022
    • Stock Exchange Compliances
      • Shareholding Pattern
        • Q4 SHP – FY 2024-25
        • Q3 SHP – FY 2024-25
        • Q2 SHP – FY 2024-25
        • Q1 SHP – FY 2024-25
        • Q4 SHP – FY 2023-24
        • Q3 SHP – FY 2023-24
        • Q2 SHP – FY 2023-24
        • Q1 SHP – FY 2023-24
        • Q4 SHP – FY 2022-23
        • Q3 SHP – FY 2022-23
        • Q2 SHP – FY 2022-23
        • Q1 SHP – FY 2022-23
        • Q4 SHP – FY 2021-22
        • Q3 SHP – FY 2021-22
        • Q2 SHP – FY 2021-22
        • Q1 SHP – FY 2021-22
      • RSCA
        • Q4 RSCA – FY 2024-25
        • Q3 RSCA – FY 2024-25
        • Q2 RSCA – FY 2024-25
        • Q1 RSCA – FY 2024-25
        • Q4 RSCA – FY 2023-24
        • Q3 RSCA – FY 2023-24
        • Q2 RSCA – FY 2023-24
        • Q1 RSCA – FY 2023-24
        • Q4 RSCA – FY 2022-23
        • Q3 RSCA – FY 2022-23
        • Q2 RSCA – FY 2022-23
        • Q1 RSCA – FY 2022-23
        • Q4 RSCA – FY 2021-22
        • Q3 RSCA – FY 2021-22
        • Q2 RSCA – FY 2021-22
        • Q1 RSCA – FY 2021-22
      • RPT
        • H2 RPT – FY 2023-24
        • H1 RPT – FY 2023-24
        • H2 RPT – FY 2022-23
        • H1 RPT – FY 2022-23
        • H2 RPT – FY 2021-22
        • H1 RPT – FY 2021-22
        • H2 RPT – FY 2020-21
        • H1 RPT – FY 2020-21
        • H2 RPT – FY 2019-20
      • Investor Complaints
        • Q4 ICR – FY 2024-25
        • Q3 ICR – FY 2024-25
        • Q2 ICR – FY 2024-25
        • Q1 ICR – FY 2024-25
        • Q4 ICR – FY 2023-24
        • Q3 ICR – FY 2023-24
        • Q2 ICR – FY 2023-24
        • Q1 ICR – FY 2023-24
        • Q4 ICR – FY 2022-23
        • Q3 ICR – FY 2022-23
        • Q2 ICR – FY 2022-23
        • Q1 ICR – FY 2022-23
        • Q4 ICR – FY 2021-22
        • Q3 ICR – FY 2021-22
        • Q2 ICR – FY 2021-22
        • Q1 ICR – FY 2021-22
    • Newspaper Publications
      • NC – Q4 Results – FY 2024-25
      • NC – Q3 Results – FY 2024-25
      • NC – Q2 Results – FY 2024-25
      • NC – Notice of AGM on 30-09-2024
      • NC – Notice of AGM on 30-09-2023
      • NC – Q1 Results – FY 2024-25
      • NC – Q4 Results – FY 2023-24
      • NC – Q3 Results – FY 2023-24
      • NC – Q2 Results – FY 2023-24
      • NC – Q1 Results – FY 2023-24
      • NC – Q4 Results – FY 2022-23
      • NC – Q3 Results – FY 2022-23
      • NC – Q2 Results – FY 2022-23
      • NC – Notice of AGM on 30-09-2022
      • NC – NBM on 13-08-2022
      • NC – Q1 Results – FY 2022-23
    • Secretarial Compliance Reports
      • SCR FY 2023-24
      • SCR FY 2022-23
      • SCR FY 2021-22
      • SCR FY 2020-21
      • SCR FY 2019-20
  • Contact Us

Details of Business

Roopa Industries Limited is into the manufacture of bulk drugs, drug intermediates and fine chemicals , with all the licenses and approvals. The facility is located at Hyderabad, the city famed as chemical capital of India.

The flagship product of the company is Triphenylphosphine, which is developed in-house , as an import substitute. The company is the first and the largest manufacture the product in India. The company has almost all the major players of Indian Pharma Industry, as clients, for the product.

The company has been manufacturing Glucosamine salts and exporting.

The company is quality conscious; environment caring; and customer oriented. The philosophy and vision of the company is “Growth achieved by mutuality”.

© 2025 · Investorsatril · All contents copyright 2011 Roopa Industries. All rights reserved.